AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca has been a top-performing stock since 2014. Management recently rolled out an $80 billion sales target for 2030.
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious.
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca just wrapped up its last strategic plan successfully. It's now setting a new ambition to be completed by 2030.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
AstraZeneca: Leading banks hail Soriot's $80bn target; more detail sought
Shares in AstraZeneca PLC (LSE:AZN) were trading just off their all-time high as leading analysts provided a largely positive assessment of its growth plans, the highlight of which was a 2030 revenue target of $80 billion - a 75% increase on last year's total. There were some reservations following the drugs giant's investor day hosted by CEO Pascal Soriot, notably around its aspirations to grow the operating profit margin to 35%.
AstraZeneca: Leading banks hail Soriot's $80bn target; more detail sought
Shares in AstraZeneca PLC (LSE:AZN) were trading just off their all-time high as leading analysts provided a largely positive assessment of its growth plans, the highlight of which was a 2030 revenue target of $80 billion - a 75% increase on last year's total. There were some reservations following the drugs giant's investor day hosted by CEO Pascal Soriot, notably around its aspirations to grow the operating profit margin to 35%.
AstraZeneca Rises to Record High After Announcing Plans for 'New Era of Growth'
AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish drug maker announced what it called its “bold ambition” for future growth.
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
